However, a comparison of safety signals associated with the use of DPP-4 inhibitors across the years showed an upward trend in adverse event signals, showing an increase in ROR, PPR, and EBGM values, especially in the post-COVID-19 pandemic compared to previous years. Here, DPP4 is linked to COVID-19.